المؤلفون: Hortobagyi, G.N., Lacko, A., Sohn, J., Cruz, F., Ruiz Borrego, M., Manikhas, A., Hee Park, Y., Stroyakovskiy, D., Yardley, D.A., Huang, C.-S., Fasching, P.A., Crown, J., Bardia, A., Chia, S., Im, S.-A., Martin, M., Loi, S., Xu, B., Hurvitz, S., Barrios, C., Untch, M., Moroose, R., Visco, F., Parnizari, F., Zarate, J.P., Li, Z., Waters, S., Chakravartty, A., Slamon, D.

المساهمون: Novartis Pharmaceuticals Corporation

المصدر: Annals of Oncology ; volume 36, issue 2, page 149-157 ; ISSN 0923-7534

الاتاحة: https://doi.org/10.1016/j.annonc.2024.10.015
https://api.elsevier.com/content/article/PII:S092375342404064X?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S092375342404064X?httpAccept=text/plain

المؤلفون: Hurvitz S. A., Hegg R., Chung W. -P., Im S. -A., Jacot W., Ganju V., Chiu J. W. Y., Xu B., Hamilton E., Madhusudan S., Iwata H., Altintas S., Henning J. -W., Curigliano G., Perez-Garcia J. M., Kim S. -B., Petry V., Huang C. -S., Li W., Frenel J. -S., Antolin S., Yeo W., Bianchini G., Loi S., Tsurutani J., Egorov A., Liu Y., Cathcart J., Ashfaque S., Cortes J.

المساهمون: Hurvitz, S. A., Hegg, R., Chung, W. -P., Im, S. -A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., Iwata, H., Altintas, S., Henning, J. -W., Curigliano, G., Perez-Garcia, J. M., Kim, S. -B., Petry, V., Huang, C. -S., Li, W., Frenel, J. -S., Antolin, S., Yeo, W., Bianchini, G., Loi, S., Tsurutani, J., Egorov, A., Liu, Y., Cathcart, J., Ashfaque, S., Cortes, J.

Relation: info:eu-repo/semantics/altIdentifier/pmid/36495879; info:eu-repo/semantics/altIdentifier/wos/WOS:000924006800001; volume:401; issue:10371; firstpage:105; lastpage:117; numberofpages:13; journal:THE LANCET; https://hdl.handle.net/20.500.11768/161736

الاتاحة: https://hdl.handle.net/20.500.11768/161736
https://doi.org/10.1016/S0140-6736(22)02420-5
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02420-5/fulltext

المؤلفون: Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L.A., Gelmon, K., Hortobagyi, G.N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W., Winer, E.

المصدر: Annals of Oncology ; volume 34, issue 7, page 630 ; ISSN 0923-7534

الاتاحة: https://doi.org/10.1016/j.annonc.2022.12.005
https://api.elsevier.com/content/article/PII:S0923753422047731?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753422047731?httpAccept=text/plain

المؤلفون: Hurvitz S. A., Bachelot T., Bianchini G., Harbeck N., Loi S., Park Y. H., Prat A., Gilham L., Boulet T., Monturus N. G. E., Lambertini C., Nyawira B., Knott A., Restuccia E., Schmid P.

المساهمون: Hurvitz, S. A., Bachelot, T., Bianchini, G., Harbeck, N., Loi, S., Park, Y. H., Prat, A., Gilham, L., Boulet, T., Monturus, N. G. E., Lambertini, C., Nyawira, B., Knott, A., Restuccia, E., Schmid, P.

مصطلحات موضوعية: ado-trastuzumab emtansine, atezolizumab, cancer immunotherapy, early breast cancer, HER2

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000888964200001; volume:18; issue:32; firstpage:3563; lastpage:3572; numberofpages:10; journal:FUTURE ONCOLOGY; https://hdl.handle.net/20.500.11768/161457

الاتاحة: https://hdl.handle.net/20.500.11768/161457
https://doi.org/10.2217/fon-2022-0485
https://www.tandfonline.com/doi/full/10.2217/fon-2022-0485

المؤلفون: Cortes J., Hurvitz S. A., Im S. -A., Iwata H., Curigliano G., Kim S. -B., Chiu J. W. Y., Pedrini J. L., Li W., Yonemori K., Bianchini G., Loi S., Borges G. S., Wang X., Bachelot T., Nakatani S., Ashfaque S., Liang Z., Egorov A., Hamilton E.

المساهمون: Cortes, J., Hurvitz, S. A., Im, S. -A., Iwata, H., Curigliano, G., Kim, S. -B., Chiu, J. W. Y., Pedrini, J. L., Li, W., Yonemori, K., Bianchini, G., Loi, S., Borges, G. S., Wang, X., Bachelot, T., Nakatani, S., Ashfaque, S., Liang, Z., Egorov, A., Hamilton, E.

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:001236852700001; volume:30; issue:8; firstpage:2208; lastpage:2215; numberofpages:8; journal:NATURE MEDICINE; https://hdl.handle.net/20.500.11768/172578

الاتاحة: https://hdl.handle.net/20.500.11768/172578
https://doi.org/10.1038/s41591-024-03021-7

المؤلفون: Curigliano G., Mueller V., Borges V., Hamilton E., Hurvitz S., Loi S., Murthy R., Okines A., Paplomata E., Cameron D., Carey L. A., Gelmon K., Hortobagyi G. N., Krop I., Loibl S., Pegram M., Slamon D., Ramos J., Feng W., Winer E.

المساهمون: G. Curigliano, V. Mueller, V. Borge, E. Hamilton, S. Hurvitz, S. Loi, R. Murthy, A. Okine, E. Paplomata, D. Cameron, L.A. Carey, K. Gelmon, G.N. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, J. Ramo, W. Feng, E. Winer

مصطلحات موضوعية: brain metastase, capecitabine, human epidermal growth factor receptor 2-positive (HER2), metastatic breast cancer, trastuzumab, tucatinib, Settore MED/06 - Oncologia Medica

Relation: info:eu-repo/semantics/altIdentifier/pmid/34954044; info:eu-repo/semantics/altIdentifier/wos/WOS:000755659500011; volume:33; issue:3; firstpage:321; lastpage:329; numberofpages:9; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/910202; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85123294615

الاتاحة: http://hdl.handle.net/2434/910202
https://doi.org/10.1016/j.annonc.2021.12.005

المؤلفون: Curigliano, G, Mueller, V, Borges, V, Hamilton, E, Hurvitz, S, Loi, S, Murthy, R, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, I, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W, Winer, E

Relation: pii: S0923-7534(21)04879-1; Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L. A., Gelmon, K., Hortobagyi, G. N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W. & Winer, E. (2022). Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol, 33 (3), pp.321-329. https://doi.org/10.1016/j.annonc.2021.12.005.; http://hdl.handle.net/11343/308715

الاتاحة: http://hdl.handle.net/11343/308715

المؤلفون: Gennari, A., Andre, F., Barrios, C. H., Cortes, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., Im, S. -a., Krug, D., Kunz, W. G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H. S., Saura, C., Schmid, P., Singer, C. F., Spanic, T., Tolaney, S. M., Turner, N. C., Curigliano, G., Loibl, S., Paluch-Shimon, S., Harbeck, N., ESMO Guidelines Committee

المساهمون: 임석아, Im, S. -a.

مصطلحات موضوعية: INTERNATIONAL CONSENSUS GUIDELINES, ALPELISIB PLUS FULVESTRANT, GERMLINE BRCA MUTATION, DOUBLE-BLIND, OPEN-LABEL, PHYSICIANS CHOICE, SACITUZUMAB GOVITECAN, TRASTUZUMAB EMTANSINE, REPORTED OUTCOMES, ENDOCRINE THERAPY, diagnosis, ESCAT, ESMO Clinical Practice Guideline, ESMO-MCBS, metastatic breast cancer, treatment

Relation: Annals of Oncology, Vol.32 No.12, pp.1475-1495; 153495; https://hdl.handle.net/10371/179242; 000721610600008; 2-s2.0-85120812833

الاتاحة: https://hdl.handle.net/10371/179242
https://doi.org/10.1016/j.annonc.2021.09.019

المؤلفون: Onesti C. E., Rugo H. S., Generali D., Peeters M., Zaman K., Wildiers H., Harbeck N., Martin M., Cristofanilli M., Cortes J., Tjan-Heijnen V., Hurvitz S. A., Berchem G., Tagliamento M., Campone M., Bartsch R., De Placido S., Puglisi F., Rottey S., Muller V., Ruhstaller T., MacHiels J. -P., Conte P., Awada A., Jerusalem G.

المساهمون: Onesti, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., Muller, V., Ruhstaller, T., Machiels, J. -P., Conte, P., Awada, A., Jerusalem, G.

مصطلحات موضوعية: COVID-19, oncological care, Betacoronaviru, Cancer Care Facilitie, Coronavirus Infection, Delivery of Health Care, Disinfection, Europe, Health Care Survey, Human, Medical Oncology, Neoplasm, Pandemic, Personal Protective Equipment, Pneumonia, Viral, SARS-CoV-2, Triage, United State, Visitors to Patients

Relation: info:eu-repo/semantics/altIdentifier/pmid/32847836; info:eu-repo/semantics/altIdentifier/wos/WOS:000567378100006; volume:5; issue:4; firstpage:"-"; lastpage:"-"; numberofpages:8; journal:ESMO OPEN; http://hdl.handle.net/11368/2993105; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85089988945; https://www.sciencedirect.com/science/article/pii/S2059702920326648?via=ihub#!; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451457/

الاتاحة: http://hdl.handle.net/11368/2993105
https://doi.org/10.1136/esmoopen-2020-000853
https://www.sciencedirect.com/science/article/pii/S2059702920326648?via=ihub#!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451457/

المؤلفون: Curigliano, G., Murthy, R., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Cameron, D., Borges, V., Bedard, P., Oliveira, M., Jakobsen, E. H., Bachelot, T., Shachar, S. S., Mueller, V., Carey, L. A., Loibl, S., Feng, W., Walker, L. N., Winer, E.

المصدر: Curigliano , G , Murthy , R , Loi , S , Okines , A , Paplomata , E , Hamilton , E , Hurvitz , S A , Cameron , D , Borges , V , Bedard , P , Oliveira , M , Jakobsen , E H , Bachelot , T , Shachar , S S , Mueller , V , Carey , L A , Loibl , S , Feng , W , Walker , L N & Winer , E 2020 , ' Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic ....

الاتاحة: https://portal.findresearcher.sdu.dk/da/publications/1fc3a435-2a58-47ea-a381-00e2d80af4a7
https://doi.org/10.1016/j.annonc.2020.03.238

المؤلفون: Lin N. U., Borges V., Anders C., Murthy R. K., Paplomata E., Hamilton E., Hurvitz S., Loi S., Okines A., Abramson V., Bedard P. L., Oliveira M., Mueller V., Zelnak A., DiGiovanna M. P., Bachelot T., Jo Chien A., O'Regan R., Wardley A., Conlin A., Cameron D., Carey L., Curigliano G., Gelmon K., Loibl S., Mayor J., McGoldrick S., An X., Winer E. P.

المساهمون: N.U. Lin, V. Borge, C. Ander, R.K. Murthy, E. Paplomata, E. Hamilton, S. Hurvitz, S. Loi, A. Okine, V. Abramson, P.L. Bedard, M. Oliveira, V. Mueller, A. Zelnak, M.P. Digiovanna, T. Bachelot, A. Jo Chien, R. O'Regan, A. Wardley, A. Conlin, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, S. Loibl, J. Mayor, S. Mcgoldrick, X. An, E.P. Winer

مصطلحات موضوعية: Adult, Aged, Antineoplastic Combined Chemotherapy Protocol, Brain Neoplasm, Breast Neoplasm, Capecitabine, Disease Progression, Double-Blind Method, Female, Human, Middle Aged, Oxazole, Pyridine, Quinazoline, Receptor, ErbB-2, Trastuzumab, Young Adult, Settore MED/06 - Oncologia Medica

Relation: info:eu-repo/semantics/altIdentifier/pmid/32468955; info:eu-repo/semantics/altIdentifier/wos/WOS:000559991300004; volume:38; issue:23; firstpage:2610; lastpage:2619; numberofpages:10; journal:JOURNAL OF CLINICAL ONCOLOGY; http://hdl.handle.net/2434/824756; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85086111080

الاتاحة: http://hdl.handle.net/2434/824756
https://doi.org/10.1200/JCO.20.00775

المؤلفون: Lin, N, Murthy, R, Anders, C, Borges, V, Hurvitz, S, Loi, S, Abramson, V, Bedard, P, Oliveira, M, Zelnack, A, DiGiovanna, M, Bachelot, T, Chien, AJ, O’Regan, R, Wardley, A, Mueller, V, Carey, L, McGoldrick, S, An, X, Winer, E

Relation: Lin, N., Murthy, R., Anders, C., Borges, V., Hurvitz, S., Loi, S., Abramson, V., Bedard, P., Oliveira, M., Zelnack, A., DiGiovanna, M., Bachelot, T., Chien, A. J., O’Regan, R., Wardley, A., Mueller, V., Carey, L., McGoldrick, S., An, X. & Winer, E. (2020). 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). [Abstract]. Neuro-Oncology Advances, 2 (Supplement_2), pp.ii11-ii11. https://doi.org/10.1093/noajnl/vdaa073.041.; http://hdl.handle.net/11343/273862

الاتاحة: http://hdl.handle.net/11343/273862

المؤلفون: Lin, NU, Borges, V, Anders, C, Murthy, RK, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, PL, Oliveira, M, Mueller, V, Zelnak, A, DiGiovanna, MP, Bachelot, T, Chien, AJ, O'Regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, McGoldrick, S, An, X, Winer, EP

Relation: Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., Bedard, P. L., Oliveira, M., Mueller, V., Zelnak, A., DiGiovanna, M. P., Bachelot, T., Chien, A. J., O'Regan, R., Wardley, A. ,. Winer, E. P. (2020). Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. JOURNAL OF CLINICAL ONCOLOGY, 38 (23), pp.2610-+. https://doi.org/10.1200/JCO.20.00775.; http://hdl.handle.net/11343/287098

الاتاحة: http://hdl.handle.net/11343/287098

المؤلفون: Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Muller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., Winer, E. P.

المصدر: Murthy , R K , Loi , S , Okines , A , Paplomata , E , Hamilton , E , Hurvitz , S A , Lin , N U , Borges , V , Abramson , V , Anders , C , Bedard , P L , Oliveira , M , Jakobsen , E , Bachelot , T , Shachar , S S , Muller , V , Braga , S , Duhoux , F P , Greil , R , Cameron , D , Carey , L A , Curigliano , G , Gelmon , K , ....

مصطلحات موضوعية: Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Brain Neoplasms/secondary, Breast Neoplasms/drug therapy, Capecitabine/administration & dosage, Consolidation Chemotherapy, Diarrhea/chemically induced, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Progression-Free Survival, Protein-Tyrosine Kinases/antagonists & inhibitors, Receptor, ErbB-2/analysis, Trastuzumab/administration & dosage

وصف الملف: application/pdf

الاتاحة: https://portal.findresearcher.sdu.dk/da/publications/68464b3b-6eae-4ed1-9926-219625af6304
https://doi.org/10.1056/NEJMoa1914609
https://findresearcher.sdu.dk/ws/files/170528833/NEJMoa1914609.pdf

المؤلفون: Barcenas, C H, Hurvitz, S A, Di Palma, J A, Bose, R, Chien, A J, Iannotti, N, Marx, G, Brufsky, A, Litvak, A, Ibrahim, E, Alvarez, R H, Ruiz-Borrego, M, Chan, N, Manalo, Y, Kellum, A, Trudeau, M, Thirlwell, M, Garcia Saenz, J, Hunt, D, Bryce, R, McCulloch, L, Rugo, H S, Tripathy, D, Chan, A, CONTROL Study Investigators

مصطلحات موضوعية: HER2-positive breast cancer, diarrhea prophylaxis, neratinib, quality of life, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Humans, Quinolines, Receptor, ErbB-2, Trastuzumab

Relation: http://hdl.handle.net/10668/15648; http://www.annalsofoncology.org/article/S0923753420398331/pdf

الاتاحة: http://hdl.handle.net/10668/15648
https://doi.org/10.1016/j.annonc.2020.05.012
http://www.annalsofoncology.org/article/S0923753420398331/pdf

المؤلفون: Masuda, N., Hurvitz, S., Vahdat, L., Harbeck, N., Wolff, A.C., Tolaney, S.M., Loi, S., O'Shaughnessy, J., Xie, D., Walker, L., Rustia, E., Borges, V.F.

المصدر: Annals of Oncology ; volume 31, page S1267-S1268 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.10.087
https://api.elsevier.com/content/article/PII:S0923753420425785?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753420425785?httpAccept=text/plain

المؤلفون: Tripathy D., Im S. -A., Colleoni M., Franke F., Bardia A., Harbeck N., Hurvitz S. A., Chow L., Sohn J., Lee K. S., Campos-Gomez S., Villanueva Vazquez R., Jung K. H., Babu K. G., Wheatley-Price P., De Laurentiis M., Im Y. -H., Kuemmel S., El-Saghir N., Liu M. -C., Carlson G., Hughes G., Diaz-Padilla I., Germa C., Hirawat S., Lu Y. -S.

المساهمون: Tripathy, D., Im, S. -A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva Vazquez, R., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y. -H., Kuemmel, S., El-Saghir, N., Liu, M. -C., Carlson, G., Hughes, G., Diaz-Padilla, I., Germa, C., Hirawat, S., Lu, Y. -S.

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000437342400050; volume:19; issue:7; firstpage:904; lastpage:915; numberofpages:12; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11588/844198; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85047257394; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549667/

الاتاحة: http://hdl.handle.net/11588/844198
https://doi.org/10.1016/S1470-2045(18)30292-4
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549667/

المؤلفون: Jhaveri, K, Eli, L D, Wildiers, H, Hurvitz, S A, Guerrero-Zotano, A, Unni, N, Brufsky, A, Park, H, Waisman, J, Yang, E S, Spanggaard, I, Reid, S, Burkard, M E, Vinayak, S, Prat, A, Arnedos, M, Bidard, F-C, Loi, S, Crown, J, Bhave, M, Piha-Paul, S A, Suga, J M, Chia, S, Saura, C, Garcia-Saenz, J Á, Gambardella, V, de Miguel, M J, Gal-Yam, E N, Rapael, A, Stemmer, S M, Ma, C, Hanker, A B, Ye, D, Goldman, J W, Bose, R, Peterson, L, Bell, J S K, Frazier, A, DiPrimeo, D, Wong, A, Arteaga, C L, Solit, D B

المصدر: Ann Oncol ; ISSN:1569-8041 ; Volume:34 ; Issue:10

مصطلحات موضوعية: ERBB2, HER2-mutant, hormone receptor-positive, metastatic breast cancer, neratinib

Relation: https://doi.org/10.1016/j.annonc.2023.08.003; https://pubmed.ncbi.nlm.nih.gov/37597578; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335023/

الاتاحة: https://doi.org/10.1016/j.annonc.2023.08.003
https://pubmed.ncbi.nlm.nih.gov/37597578
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335023/

المؤلفون: Turner, N. C., Laird, A. D., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E. M., Mina, L. A., Balmaña, J., Fasching, P. A., Hurvitz, S. A., Hopkins, J. F., Albacker, L. A., Chelliserry, J., Chen, Y., Conte, U., Wardley, Andrew M, Robson, M. E.

المساهمون: The Royal Marsden Hospital, The Institute of Cancer Research, London, UK

Relation: https://dx.doi.org/10.1038/s41523-023-00561-y; Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer. 2023 Oct 6;9(1):81. PubMed PMID: 37803017. Pubmed Central PMCID: PMC10558443 financial interests: advisory board honoraria from AstraZeneca, Exact Sciences, Gilead Sciences, GSK, Guardant, Inivata, Lilly, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, Roche/Genentech, and Zentalis; and research funding from AstraZeneca, Guardant Health, Inivata, Invitae, Merck Sharp & Dohme, Natera, Personalis, Pfizer, and Roche/Genentech. ADL, JC, and UC declare no competing non-financial interests but the following competing financial interests: employees of Pfizer and own stocks in Pfizer. MLT declares no competing non-financial interests but the following competing financial interests: research funding (to her institution) from AbbVie, Arvinas, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GSK, Hummingbird Biosciences, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro and Vertex; and consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Gilead Sciences, GSK, G1 Therapeutics, Guardant, Immunomedics, Merck, Natera, Novartis, OncoSec, Pfizer, RefleXion, Replicate, Roche/Genentech, and Sanofi. HSR declares no competing non-financial interests but the following competing financial interests: research support to the University of California San Francisco from Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Lilly, Merck & Co., Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Roche/Genentech, Sermonix Pharmaceuticals, Taiho Oncology, and Veru; travel support to academic meetings from AstraZeneca, Gilead Sciences, and Merck; and consultancy/advisory support from Blueprint, NAPO, Puma, and Scorpion Therapeutics. AM declares no competing non-financial interests but the following competing financial interests: honoraria from Pfizer, and travel/accommodation support from AstraZeneca and Pierre Fabre. JE declares no competing non-financial interests but the following competing financial interests: consulting fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Tesaro; contracted research from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Odonate, Pfizer, Roche, and Seattle Genetics; and travel support from AstraZeneca, Celgene, Daiichi Sankyo, Lilly, Novartis, Pfizer, and Tesaro. E-MG and LAM have nothing to disclose. JB declares no competing non-financial interests but the following competing financial interests: consultant/advisory board member for AstraZeneca and Pfizer; and submitted a European patent request (EP17382884.9). PAF declares no competing non-financial interests but the following competing financial interests: commercial research grants from Novartis to his institution; speakers bureau honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva; and consultant/advisory board member for Celgene, Daiichi Sankyo, Novartis, Pfizer, Puma, Roche, and Teva. SAH declares the following non-financial interests: unpaid TRIO-US Chief Medical Officer (until Jan 2023), unpaid consultant/steering committee member for Arvinas, AstraZeneca, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Gilead Sciences, Greenwich Life Sciences, Immunomedics, Lilly, MacroGenics, Novartis, Orum, Pieris Pharmaceuticals, Puma Biotechnology, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, Zymeworks; and the following competing financial interests: contracted research support (which may include editorial assistance) from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, BioMarin, Cascadian Therapeutics, Celcuity, Cyomx, Daiichi Sankyo, Dantari, Dignitana, G1 Therapeutics, Gilead Sciences, Greenwich Life Sciences, GSK, Immunomedics, Lilly, MacroGenics, Merrimack, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Design, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche/Genentech, Sanofi, Seattle Genetics/SeaGen, and Zymeworks. JFH was an employee of Foundation Medicine, Inc. and a stockholder of Roche Holding AG when the study was carried out. LAA declares no competing non-financial interests but the following competing financial interests: employee of Foundation Medicine, Inc. and owns stocks in Roche Holdings AG. YC declares no competing non-financial interests but the following competing financial interests: contractor at Pfizer (until 2021) at the time the work was performed. AMW declares no competing non-financial interests but the following competing financial interests (at the time of the study): consultancy fees from ACCORD, Amgen, AstraZeneca, Athenex, Daiichi Sankyo, Lilly, MSD, NAPP, Novartis, Pfizer, Pierre Fabre, Roche, and Takeda; reimbursement from Amgen, Daiichi Sankyo, and Roche; speaker fees from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; and research funding from Lilly, Novartis, Pfizer, and Roche. He was NCRI Breast Research Group early breast cancer systemic anti-cancer therapy lead 2014–21, ACP strategy director 2018–21, and a member of NHSE Clinical reference group for systemic anti-cancer therapy 2013–21 and clinical advisor to NICE for same period (all unremunerated). He left the NHS in January 2021 and worked for AstraZeneca until March 2022, when he left to concentrate fulltime on Outreach Research & Innovation Group (a company he founded to improve access to clinical trials for cancer patients). He has given talks for Roche and Seagen separately through Andrew Wardley Limited. MER declares no competing non-financial interests but the following competing financial interests: research funding from AstraZeneca and Pfizer; past research funding from AbbVie, Medivation, and Tesaro (at the time the work was performed); travel, accommodation, and expenses from AstraZeneca and other transfer of value from AstraZeneca and Pfizer. Epub 2023/10/07. eng.; http://hdl.handle.net/10541/626610; NPJ Breast Cancer

الاتاحة: http://hdl.handle.net/10541/626610
https://doi.org/10.1038/s41523-023-00561-y

المؤلفون: Lu Y. -S., Im S. -A., Colleoni M., Franke F., Bardia A., Cardoso F., Harbeck N., Hurvitz S., Chow L., Sohn J., Lee K. S., Campos-Gomez S., Vazquez R. V., Jung K. H., Babu K. G., Wheatley-Price P., De Laurentiis M., Im Y. -H., Kuemmel S., El-Saghir N., O'Regan R., Gasch C., Solovieff N., Wang C., Wang Y., Chakravartty A., Ji Y., Tripathy D.

المساهمون: Lu, Y. -S., Im, S. -A., Colleoni, M., Franke, F., Bardia, A., Cardoso, F., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Vazquez, R. V., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y. -H., Kuemmel, S., El-Saghir, N., O'Regan, R., Gasch, C., Solovieff, N., Wang, C., Wang, Y., Chakravartty, A., Ji, Y., Tripathy, D.

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000767274900001; volume:28; issue:5; firstpage:851; lastpage:859; numberofpages:9; journal:CLINICAL CANCER RESEARCH; https://hdl.handle.net/11588/922366; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85125729661

الاتاحة: https://hdl.handle.net/11588/922366
https://doi.org/10.1158/1078-0432.CCR-21-3032